Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38

Futu NewsDec 16 21:33 · Ratings

Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock

Simply Wall StDec 15 20:18

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

Akero TherapeuticsNov 26 13:00

Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment

TipRanksNov 22 19:25 · Ratings

Akero a New Buy at Citi on Liver Disease Asset

Seeking AlphaNov 19 01:33

Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup

Dow JonesNov 18 20:51 · Ratings